Equities Analysts Offer Predictions for MIRM FY2026 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.61) for the year, down from their prior estimate of ($0.37). HC Wainwright has a “Buy” rating and a $202.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.32) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.68) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at $0.14 EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at $2.64 EPS, FY2029 earnings at $6.85 EPS and FY2030 earnings at $10.76 EPS.

Several other analysts also recently commented on MIRM. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings lowered shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 22nd. Stifel Nicolaus boosted their target price on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. UBS Group set a $137.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. Finally, Cantor Fitzgerald increased their target price on shares of Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $154.94.

Mirum Pharmaceuticals Trading Down 3.5%

Shares of MIRM stock opened at $93.54 on Friday. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.07. The stock has a 50 day simple moving average of $89.41 and a two-hundred day simple moving average of $98.46. The company has a market cap of $6.07 billion, a P/E ratio of -6.05 and a beta of 0.75.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 134.75% and a negative return on equity of 97.25%. The business had revenue of $185.72 million during the quarter, compared to analyst estimates of $178.07 million. During the same period in the prior year, the firm earned $0.05 earnings per share. The firm’s revenue for the quarter was up 39.6% compared to the same quarter last year.

Insider Transactions at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the sale, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $90.00, for a total value of $1,800,000.00. Following the sale, the chief executive officer owned 206,637 shares in the company, valued at $18,597,330. This trade represents a 8.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 116,659 shares of company stock valued at $11,404,100 over the last ninety days. 8.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the business. Nan Fung Trinity HK Ltd. grew its stake in shares of Mirum Pharmaceuticals by 1.6% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 222,679 shares of the company’s stock worth $19,035,000 after acquiring an additional 3,464 shares during the period. Illinois Municipal Retirement Fund bought a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $1,168,000. Knights of Columbus Asset Advisors LLC raised its stake in Mirum Pharmaceuticals by 0.5% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 23,944 shares of the company’s stock valued at $2,047,000 after acquiring an additional 113 shares during the period. Commonwealth Equity Services LLC raised its stake in Mirum Pharmaceuticals by 10.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 2,471 shares of the company’s stock valued at $211,000 after acquiring an additional 241 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at about $284,000.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 39.6% year over year to $185.72 million, topping expectations. The company also highlighted new data from its rare liver disease portfolio for an upcoming medical meeting, which could draw attention to its pipeline. Q3 results Portfolio data announcement
• Positive Sentiment: Several firms raised price targets after the earnings update: Citizens JMP to $167, HC Wainwright to $202 and Cantor Fitzgerald to $160; RBC reaffirmed its Outperform rating and $155 target. HC Wainwright also lifted its 2030 EPS forecast, although it cut estimates for earlier years. Citizens JMP rating HC Wainwright rating Cantor Fitzgerald rating
• Neutral Sentiment: CEO Christopher Peetz sold 20,000 shares for $1.8 million under a pre-arranged Rule 10b5-1 plan. The planned sale may be less concerning than an unplanned transaction, though insider selling can draw investor attention. Insider sale report
• Negative Sentiment: Mirum’s Q3 loss of $0.87 per share was wider than the $0.49 consensus loss, despite the revenue beat. Separately, HC Wainwright cut forecasts across Q4 2026 and 2027, including moving its FY2027 estimate from $1.16 earnings to a $1.28 loss, and reduced its FY2028 and FY2029 EPS projections. These revisions point to weaker expected profitability in the near and medium term, even as the firm maintained its Buy rating and $202 target. Q3 earnings call transcript
• Negative Sentiment: Leerink Partners lowered its price target to $140 from $154, though it retained an Outperform rating. Leerink Partners rating

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.